OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MBAI$1.7956

Check Cap Ltd

Biotechnology & Medical ResearchVerified

Check Cap Ltd has a market price of $1.79 and a market cap of $12,566,698.58, indicating a relatively small market capitalization. The company's financial snapshot shows that the number of shares outstanding is the same for both basic and diluted shares, at 7,020,502, suggesting no immediate dilution risk. The company's profitability is currently negative, as evidenced by the last actual EPS of -3.00, which indicates a loss per share. This loss per share is a significant concern when compared to industry standards, as it suggests the company is not generating positive returns for its shareholders at this time. There is no detailed information provided on the company's segments or geographic exposure, which limits the ability to assess revenue concentration or diversification. Without this data, it is difficult to determine the extent to which the company's performance is tied to specific markets or product lines. The company's growth trajectory is not clearly defined, as there is no outlook data provided for the current or next fiscal year. The absence of growth projections makes it challenging to assess the company's future performance or potential for expansion. The risk assessment indicates that liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents. This lack of information is a red flag for investors, as it suggests that the company's ability to meet its short-term obligations is uncertain. Recent events or filings that could impact the company's operations or financial status are not detailed in the provided data. This absence of recent events makes it difficult to gauge the company's current situation or any potential changes that may affect its performance.

30-day price · MBAI(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyCheck Cap Ltd
TickerMBAI.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Check Cap Ltd operates in the healthcare sector, specifically within the biotechnology and medical research industry, focusing on pharmaceuticals and medical research.

Classification. Check Cap Ltd is classified under the industry of Biotechnology & Medical Research within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Check Cap Ltd has a market price of $1.79 and a market cap of $12,566,698.58, indicating a relatively small market capitalization. The company's financial snapshot shows that the number of shares outstanding is the same for both basic and diluted shares, at 7,020,502, suggesting no immediate dilution risk. The company's profitability is currently negative, as evidenced by the last actual EPS of -3.00, which indicates a loss per share. This loss per share is a significant concern when compared to industry standards, as it suggests the company is not generating positive returns for its shareholders at this time. There is no detailed information provided on the company's segments or geographic exposure, which limits the ability to assess revenue concentration or diversification. Without this data, it is difficult to determine the extent to which the company's performance is tied to specific markets or product lines. The company's growth trajectory is not clearly defined, as there is no outlook data provided for the current or next fiscal year. The absence of growth projections makes it challenging to assess the company's future performance or potential for expansion. The risk assessment indicates that liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents. This lack of information is a red flag for investors, as it suggests that the company's ability to meet its short-term obligations is uncertain. Recent events or filings that could impact the company's operations or financial status are not detailed in the provided data. This absence of recent events makes it difficult to gauge the company's current situation or any potential changes that may affect its performance.
Key takeaways
  • Check Cap Ltd is a small-cap company in the biotechnology and medical research industry.
  • The company is currently reporting a loss per share, indicating poor profitability.
  • There is no immediate dilution risk as the number of basic and diluted shares is the same.
  • The company's liquidity risk could not be assessed due to insufficient data.
  • The company's growth trajectory and future performance are unclear without additional outlook data.
  • # RATIONALES
  • **margin_outlook_rationale**: The company's margin outlook is negative due to the reported loss per share.
  • **rd_outlook_rationale**: There is no specific information provided on the company's research and development outlook.
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4-$17.3M-$17.2M-$18.0M
FY-3-$20.0M-$19.1M-$19.2M
FY-2-$19.3M-$17.6M-$17.4M
FY-1-$25.9M-$25.1M-$25.0M
FY0$4.2M$4.1M$4.2M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$55.7M$50.7M$26.5M
FY-3$45.4M$41.3M$4.1M
FY-2$25.0M$23.7M$8.8M
FY-1$377.0k-$1.4M$0.00
FY0$7.5M$3.4M$2.0k
PeriodOCFCapExFCFSBC
FY-4-$16.3M-$1.0M-$18.0M
FY-3-$18.7M-$486.0k-$19.2M
FY-2-$17.0M-$83.0k-$17.4M
FY-1-$8.0M-$25.0M
FY0-$46.0k$4.2M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6-$6.3M
FQ-5
FQ-4-$18.7M
FQ-3
FQ-2$5.2M
FQ-1
FQ0-$1.1M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6$18.1M$17.2M$17.8M
FQ-5
FQ-4$377.0k-$1.4M$0.00
FQ-3
FQ-2$5.8M$3.8M$1.2M
FQ-1
FQ0$7.5M$3.4M$2.0k
PeriodOCFCapExFCFSBC
FQ-7
FQ-6-$6.9M$0.00-$6.3M
FQ-5
FQ-4-$8.0M-$18.7M
FQ-3
FQ-2$1.2M$0.00$5.2M
FQ-1
FQ0-$46.0k-$1.1M
Valuation
Market price$1.79
Market cap$12.6M
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricMBAIActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity9.3% medp25 0.1% · p75 43.8%
Observations
IR observations
Last actual EPS-3.00
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-17 01:11 UTC#2b367c6d
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 12:34 UTCJob: 44a97bd5